All In MedTech

FDA Clearance Tracker · P170019-S037

FoundationOne CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 26, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 26, 2023

Approved

Time to decision

287 days

Received Aug 12, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170019-S037
Device name
FoundationOne CDx
Applicant location
Boston, MA
Received
Aug 12, 2022
Decided
May 26, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170019

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval of the clinical protocol entitled Statistical Analysis Plan for Real-World Evidence Study Supporting FoundationOne®CDx as a Companion Diagnostic for Entrectinib in Non-Small Cell Lung Cancer Patients with ROS1 Fusions

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.